Modifications to the dNTP triphosphate moiety: From mechanistic probes for DNA polymerases to antiviral and anti-cancer drug design

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1804, Issue 5, 2010, Pages 1223-1230

  McKenna, Charles E ^a   Kashemirov, Boris A ^a   Peterson, Larryn W ^a   Goodman, Myron F ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Anti cancer; Antiviral; Bisphosphonate; DNA polymerase; Drug delivery; Drug targeting; Nucleotide analogue

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYTARABINE; DNA POLYMERASE; FLOXURIDINE; GEMCITABINE; NUCLEOSIDE ANALOG; ZIDOVUDINE;

BONE DISEASE; CHEMICAL MODIFICATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DEOXYRIBONUCLEOTIDES; DNA-DIRECTED DNA POLYMERASE; DRUG DESIGN; HUMANS; PHOSPHONIC ACIDS;

EID: 77949551370     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2010.01.005     Document Type: Review

References (80)

1. Radhakrishnan R., Arora K., Wang Y., Beard W.A., Wilson S.H., and Schlick T. Regulation of DNA repair fidelity by molecular checkpoints: "gates" in DNA polymerase beta's substrate selection. Biochemistry 45 (2006) 15142-15156
2. Joyce C.M., and Benkovic S.J. DNA polymerase fidelity: kinetics, structure, and checkpoints. Biochemistry 43 (2004) 14317-14324
3. Huang H.F., Chopra R., Verdine G.L., and Harrison S.C. Structure of a covalently trapped catalytic complex of HIV-I reverse transcriptase: implications for drug resistance. Science 282 (1998) 1669-1675
4. Li Y., Korolev S., and Waksman G. Crystal structures of open and closed forms of binary and ternary complexes of the large fragment of Thermus aquaticus DNA polymerase I: structural basis for nucleotide incorporation. EMBO J. 17 (1998) 7514-7525
5. Doublie S., Tabor S., Long A.M., Richardson C.C., and Ellenberger T. Crystal structure of a bacteriophage T7 DNA replication complex at 2.2 angstrom resolution. Nature 391 (1998) 251-258
6. Franklin M.C., Wang J.M., and Steitz T.A. Structure of the replicating complex of a pol alpha family DNA polymerase. Cell 105 (2001) 657-667
7. Sawaya M.R., Prasad R., Wilson S.H., Kraut J., and Pelletier H. Crystal structures of human DNA polymerase beta complexed with gapped and nicked DNA: evidence for an induced fit mechanism. Biochemistry 36 (1997) 11205-11215
8. Patel S.S., Wong I., and Johnson K.A. Pre-steady-state kinetic analysis of processive DNA replication including complete characterization of an exonuclease-deficient mutant. Biochemistry 30 (1991) 511-525
9. Washington M.T., Prakash L., and Prakash S. Yeast DNA polymerase eta utilizes an induced-fit mechanism of nucleotide incorporation. Cell 107 (2001) 917-927
10. Dahlberg M.E., and Benkovic S.J. Kinetic mechanism of DNA polymerase 1 (Klenow fragment): identification of a second conformational change and evaluation of the internal equilibrium constant. Biochemistry 30 (1991) 4835-4843
11. Roettger M.P., Bakhtina M., and Tsai M.-D. Mismatched and matched dNTP incorporation by DNA polymerase beta proceed via analogous kinetic pathways. Biochemistry 47 (2008) 9718-9727
12. Bakhtina M., Roettger M.P., and Tsai M.-D. Contribution of the reverse rate of the conformational step to polymerase beta fidelity. Biochemistry 48 (2009) 3197-3208
13. Berdis A.J. DNA polymerases as therapeutic targets. Biochemistry 47 (2008) 8253-8260
14. Sakaguchi K., and Sugawara F. New cancer chemotherapy agents: inhibitors of DNA polymerase. Curr. Drug Ther. 3 (2008) 44-53
15. Devadoss B., and Berdis A.J. Non-natural nucleotide analogs as probes of DNA polymerase activity. Curr. Chem. Biol. 1 (2007) 241-264
16. Robak T., Korycka A., Lech-Maranda E., and Robak P. Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules 14 (2009) 1172-1215
17. De Clercq E. Antivirals: current state of the art. Future Virol. 3 (2008) 393-405
18. Peterson L.W., and McKenna C.E. Produg approaches to improving the oral absorption of antiviral nucleotide analogues. Expert Opin. Drug Del. 6 (2009) 405-420
19. Zhang L., Strong J.M., Qiu W., Lesko L.J., and Huang S.M. Scientific perspectives on drug transporters and their role in drug interactions. Mol. Pharm. 3 (2006) 62-69
20. Wagner C.R., Iyer V.V., and McIntee E.J. Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides. Med. Res. Rev. 20 (2000) 417-451
21. Conway B. HAART in treatment-experienced patients in the 21st century: the audacity of hope. Future Virol. 4 (2009) 39-41
22. Lowe S.H., Prins J.M., and Lange J.M.A. Antiretroviral therapy in previously untreated adults infected with the human immunodeficiency virus type I: established and potential determinants of virological outcome. Neth. J. Med. 62 (2004) 424-440
23. Qian M., Bui T., Ho R.J.Y., and Unadkat J.D. Metabolism of 3′-azido-3′-deoxythymidine (AZT) in human placental trophoblasts and Hofbauer cells. Biochem. Pharmacol. 48 (1994) 383-389
24. Agarwal R.P., and Mian A.M. Thymidine and zidovudine metabolism in chronically zidovudine-exposed cells in vitro. Biochem. Pharmacol. 42 (1991) 905-911
25. Lavie A., Su Y., Ghassemi M., Novak R.M., Caffrey M., Sekulic N., Monnerjahn C., Konrad M., and Cook J.L. Restoration of the antiviral activity of 3′-azido-3′-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus by delivery of engineered thymidylate kinase to T cells. J. Gen. Virol. 89 (2008) 1672-1679
26. Petit F., Fromenty B., Owen A., and Estaquier J. Mitochondria are sensors for HIV drugs. Trends Pharmacol. Sci. 26 (2005) 258-264
27. Polo R., Martinez S., Madrigal P., and Gonzalez-Munoz M. Factors associated with mitochondrial dysfunction in circulating peripheral blood lymphocytes from HIV-infected people. J. Acquir. Immune Defic. Syndr. 34 (2003) 32-36
28. Lewis W., Day B.J., and Copeland W.C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug Discov. 2 (2003) 812-822
29. Balakrishnan L., Brandt P.D., Lindsey-Boltz L.A., Sancar A., and Bambara R.A. Long patch base excision repair proceeds via coordinated stimulation of the multienzyme DNA repair complex. J. Biol. Chem. 284 (2009) 15158-15172
30. Balusu R., Jaiswal A.S., Armas M.L., Kundu C.N., Bloom L.B., and Narayan S. Structure/function analysis of the interaction of adenomatous polyposis coli with DNA polymerase beta and its implications for base excision repair. Biochemistry 46 (2007) 13961-13974
31. Guo Z., Zheng L., Dai H., Zhou M., Xu H., and Shen B. Human DNA polymerase beta polymorphism, Arg137Gln, impairs its polymerase activity and interaction with PCNA and the cellular base excision repair capacity. Nucleic Acids Res. 37 (2009) 3431-3441
32. Donigan K.A., and Sweasy J.B. Sequence context-specific mutagenesis and base excision repair. Mol. Carcinog. 48 (2009) 362-368
33. Sucato C.A., Upton T.G., Kashemirov B.A., Batra V.K., Martinek V., Xiang Y., Beard W.A., Pedersen L.C., Wilson S.H., McKenna C.E., Florian J., Warshel A., and Goodman M.F. Modifying the beta, gamma leaving-group bridging oxygen alters nucleotide incorporation efficiency, fidelity, and the catalytic mechanism of DNA polymerase beta. Biochemistry 46 (2007) 461-471
34. McKenna C.E., Kashemirov B.A., Upton T.G., Batra V.K., Goodman M.F., Pedersen L.C., Beard W.A., and Wilson S.H. (R)-beta, gamma-fluoromethylene-dGTP-DNA ternary complex with DNA polymerase beta. J. Am. Chem. Soc. 129 (2007) 15412-15413
35. Sucato C.A., Upton T.G., Kashemirov B.A., Osuna J., Oertell K., Beard W.A., Wilson S.H., Florian J., Warshel A., McKenna C.E., and Goodman M.F. DNA polymerase beta fidelity: halomethylene-modified leaving groups in pre-steady-state kinetic analysis reveal differences at the chemical transition state. Biochemistry 47 (2008) 870-879
36. Upton T.G., Kashemirov B.A., McKenna C.E., Goodman M.F., Prakash G.K.S., Kultyshev R., Batra V.K., Shock D.D., Pedersen L.C., Beard W.A., and Wilson S.H. Alpha, beta-difluoromethylene deoxynucleoside 5′-triphosphates: a convenient synthesis of useful probes for DNA polymerase beta structure and function. Org. Lett. 11 (2009) 1883-1886
37. Kamerlin S.C.L., McKenna C.E., Goodman M.F., and Warshel A. A computational study of the hydrolysis of dGTP analogues with halomethylene-modified leaving groups in solution: implications for the mechanism of DNA polymerases. Biochemistry 48 (2009) 5963-5971
38. V.K. Batra, L.C. Pedersen, W.A. Beard, S.H. Wilson, B.A. Kashemirov, T.G. Upton, M.F. Goodman, C.E. McKenna, "Halogenated β,γ-Methylene- and Ethylidene-dGTP-DNA Ternary Complexes with DNA Polymerase β: Structural Evidence for Stereospecific Binding of the Fluoromethylene Analogues", submitted.
39. Kohno N. Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future. Int. J. Clin. Oncol. 13 (2008) 18-23
40. Lipton A. Emerging role of bisphosphonates in the clinic - antitumor activity and prevention of metastasis to bone. Cancer Treat. Rev. 34 (2008) S25-S30
41. Van den Wyngaert T., Huizing M.T., Fossion E., and Vermorken J.B. Bisphosphonates in oncology: rising stars or fallen heroes. Oncologist 14 (2009) 181-191
42. Conte P., and Coleman R. Bisphosphonates in the treatment of skeletal metastases. Semin. Oncol. 31 (2004) 59-63
43. Roelofs A.J., Thompson K., Gordon S., and Rogers M.J. Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer. Res. 12 (2006) 6222S-6230S
44. Lehenkari P.P., Kellinsalmi M., Napankangas J.P., Ylitalo K.V., Monkkonen J., Rogers M.J., Azhayev A., Vaananen H.K., and Hassinen I.E. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol. Pharmacol. 61 (2002) 1255-1262
45. Halasy-Nagy J.M., Rodan G.A., and Reszka A.A. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 29 (2001) 553-559
46. Benford H.L., Frith J.C., Auriola S., Monkkonen J., and Rogers M.J. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol. Pharmacol. 56 (1999) 131-140
47. Rogers M.J. New insights into the molecular mechanism of action of bisphosphonates. Curr. Pharm. Design 9 (2003) 2643-2658
48. Bergstrom J.D., Bostedor R.G., Masarachia P.J., Reszka A.A., and Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys. 373 (2000) 231-241
49. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., Ebetino F.H., and Rogers M.J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296 (2001) 235-242
50. Golomb G., Schlossman A., Eitan Y., Saadeh H., Vangelder J.M., and Breuer E. In vitro and in vivo anticalcification effects of novel bishydroxyiminophosphonates. J. Pharm. Sci. 81 (1992) 1004-1007
51. Grossmann G., Grossmann A., Ohms G., Breuer E., Chen R., Golomb C., Cohen H., Hagele G., and Classen R. Solid-state NMR of bisphosphonates adsorbed on hydroxyapatite. Magn. Reson. Chem. 38 (2000) 11-16
52. Pan H.Z., Sima M., Kopeckova P., Wu K., Gao S.Q., Liu J.H., Wang D., Miller S.C., and Kopecek J. Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates. Mol. Pharm. 5 (2008) 548-558
53. Erez R., Ebner S., Attali B., and Shabat D. Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activation. Bioorg. Med. Chem. Lett. 18 (2008) 816-820
54. Ora M., Lonnberg T., Florea-Wang D., Zinnen S., Karpeisky A., and Lonnberg H. Bisphosphonate derivatives of nucleoside antimetabolites: hydrolytic stability and hydroxyapatite adsorption of 5′-beta, gamma-methylene and 5′-beta, gamma-(1-hydroxyethylidene) triphosphates of 5-fluorouridine and ara-cytidine. J. Org. Chem. 73 (2008) 4123-4130
55. Arzumanov A.A., Semizarov D.G., Victorova L.S., Dyatkina N.B., and Krayevsky A.A. Gamma-phosphate-substituted 2′-deoxynucleoside 5′-triphosphates as substrates for DNA polymerases. J. Biol. Chem. 271 (1996) 24389-24394
56. Alexandrova L.A., Skoblov A.Y., Jasko M.V., Victorova L.S., and Krayevsky A.A. 2′-Deoxynucleoside 5′-triphosphates modified at alpha-, beta- and gamma-phosphates as substrates for DNA polymerases. Nucleic Acids Res. 26 (1998) 778-786
57. Mulder B.A., Anaya S., Yu P., Lee K.W., Nguyen A., Murphy J., Willson R., Briggs J.M., Gao X., and Hardin S.H. Nucleotide modification at the gamma-phosphate leads to the improved fidelity of HIV-1 reverse transcriptase. Nucleic Acids Res. 33 (2005) 4865-4873
58. Eid J., Fehr A., Gray J., Luong K., Lyle J., Otto G., Peluso P., Rank D., Baybayan P., Bettman B., Bibillo A., Bjornson K., Chaudhuri B., Christians F., Cicero R., Clark S., Dalal R., de Winter A., Dixon J., Foquet M., Gaertner A., Hardenbol P., Heiner C., Hester K., Holden D., Kearns G., Kong X., Kuse R., Lacroix Y., Lin S., Lundquist P., Ma C., Marks P., Maxham M., Murphy D., Park I., Pham T., Phillips M., Roy J., Sebra R., Shen G., Sorenson J., Tomaney A., Travers K., Trulson M., Vieceli J., Wegener J., Wu D., Yang A., Zaccarin D., Zhao P., Zhong F., Korlach J., and Turner S. Real-time DNA sequencing from single polymerase molecules. Science (Washington, DC, U. S.) 323 (2009) 133-138
59. Levene M.J., Korlach J., Turner S.W., Foquet M., Craighead H.G., and Webb W.W. Zero-mode waveguides for single-molecule analysis at high concentrations. Science (Washington, DC, U. S.) 299 (2003) 682-686
60. Kumar S., Sood A., Wegener J., Finn P.J., Nampalli S., Nelson J.R., Sekher A., Mitsis P., Macklin J., and Fuller C.W. Terminal phosphate labeled nucleotides: synthesis, applications, and linker effect on incorporation by DNA polymerases. Nucleosides Nucleotides Nucleic Acids 24 (2005) 401-408
61. Sood A., Kumar S., Nampalli S., Nelson J.R., Macklin J., and Fuller C.W. Terminal phosphate-labeled nucleotides with improved substrate properties for homogeneous nucleic acid assays. J. Am. Chem. Soc. 127 (2005) 2394-2395
62. Meyer P.R., Matsuura S.E., So A.G., and Scott W.A. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 13471-13476
63. Meyer P.R., Smith A.J., Matsuura S.E., and Scott W.A. Chain-terminating dinucleoside tetraphosphates are substrates for DNA polymerization by human immunodeficiency virus type 1 reverse transcriptase with increased activity against thymidine analog-resistant mutants. Antimicrob. Agents Chemother. 50 (2006) 3607-3614
64. Victorova L., Sosunov V., Skoblov A., Shipytsin A., and Krayevsky A. New substrates of DNA polymerases. FEBS Lett. 453 (1999) 6-10
65. Skoblov A.Y., Sosunov V.V., Victorova L.S., Skoblov Y.S., and Kukhanova M.K. Substrate properties of dinucleoside 5′,5″-oligophosphates in the reactions catalyzed by HIV reverse transcriptase, E. coli DNA polymerase I, and E. coli RNA polymerase, Russ. J. Bioorg. Chem. 31 (2005) 48-57
66. Jochmans D. Novel HIV-1 reverse transcriptase inhibitors. Virus Res. 134 (2008) 171-185
67. Shaw B.R., Sergueev D., He K., Porter K., Summers J., Sergueeva Z., and Rait V. Boranophosphate backbone: a mimic of phosphodiesters, phosphorothioates, and methyl phosphonates. Methods Enzymol. 313 (2000) 226-257
68. Shaw B.R., Dobrikov M., Wang X., Wan J., He K., Lin J.-L., Li P., Rait V., Sergueeva Z.A., and Sergueev D. Reading, writing, and modulating genetic information with boranophosphate mimics of nucleotides, DNA, and RNA. Ann. N. Y. Acad. Sci. 1002 (2003) 12-29
69. Alvarez K., Deval J., Selmi B., Barral K., Boretto J., Guerreiro C., Mulard L., Sarfati R., and Canard B. Borano-nucleotides: new analogues to circumvent HIV-1 RT-mediated nucleoside drug-resistance. Nucleosides Nucleotides Nucleic Acids 24 (2005) 419-421
70. Meyer P.R., Matsuura S.E., Mian A.M., So A.G., and Scott W.A. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4 (1999) 35-43
71. Arion D., Kaushik N., McCormick S., Borkow G., and Parniak M.A. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37 (1998) 15908-15917
72. Cheek M.A., Dobrikov M.I., Wennefors C.K., Xu Z., Hashmi S.N., Shen X., and Shaw B.R. Synthesis and properties of (α-P-borano)-nucleoside 5′-triphosphate analogues as potential antiviral agents. Nucleic Acids Symp. Ser. (2008) 81-82
73. Vinogradov S.V., Zeman A.D., Batrakova E.V., and Kabanov A.V. Polyplex nanogel formulations for drug delivery of cytotoxic nucleoside analogs. J. Control. Release 107 (2005) 143-157
74. Wang G., Boyle N., Chen F., Rajappan V., Fagan P., Brooks J.L., Hurd T., Leeds J.M., Rajwanshi V.K., Jin Y., Prhavc M., Bruice T.W., and Cook P.D. Synthesis of AZT 5′-triphosphate mimics and their inhibitory effects on HIV-1 reverse transcriptase. J. Med. Chem. 47 (2004) 6902-6913
75. Boyle N., Fagan P., Brooks J., Prhavc M., Lambert J., and Cook P.D. 2′, 3′-Dideoxynucleoside 5′-beta, gamma-(difluoromethylene) triphosphates with alpha-P-thio or alpha-P-seleno modifications: synthesis and their inhibition of HIV-1 reverse transcriptase. Nucleosides Nucleotides Nucleic Acids 24 (2005) 1651-1664
76. Schulz T., Jessen H.J., Balzarini J., and Meier C. Bioreversible protection of nucleosidediphosphates - synthesis and properties. Antiviral Res. 82 (2009) A63
77. Vinogradov S.V., Kohli E., and Zeman A.D. Comparison of nanogel drug carriers and their formulations with nucleoside 5′-triphosphates. Pharm. Res. 23 (2006) 920-930
78. Galmarini C.M., Warren G., Kohli E., Zeman A., Mitin A., and Vinogradov S.V. Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines. Mol. Cancer Ther. 7 (2008) 3373-3380
79. Raemdonck K., Demeester J., and De Smedt S. Advanced nanogel engineering for drug delivery. Soft Matter 5 (2009) 707-715
80. Showalter A.K., and Tsai M.-D. A reexamination of the nucleotide incorporation fidelity of DNA polymerases. Biochemistry 41 (2002) 10571-10576